Soleno Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLNO research report →
Range $53 – $107
Price Chart
About the company
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation.
- CEO
- Anish Bhatnagar
- IPO
- 2014
- Employees
- 115
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on SLNO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.76B
- P/E
- 27.09
- Fwd P/E
- 13.91
- PEG
- 0.02
- P/S
- 9.69
- P/B
- 5.57
- EV/EBITDA
- 24.62
- Div Yield
- 0.00%
- Gross Margin
- 98.63%
- Op Margin
- 30.80%
- Net Margin
- 33.70%
- ROE
- 22.86%
- ROIC
- 15.35%
Latest fiscal year · YoY change
- Revenue
- $190.41M+0.0%
- Gross Profit
- $187.71M+0.0%
- Op Income
- $14.95M
- Net Income
- $20.89M+111.9%
- EPS
- $0.41+109.4%
- OCF Growth
- +167.7%
- FCF Growth
- +167.4%
- 52W High
- $90.32
- 52W Low
- $29.43
- 50D MA
- $45.78
- 200D MA
- $51.16
- Beta
- -2.22
- RSI (14)
- 78
- Avg Volume
- 3.45M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Soleno ended 2025 with strong VYKAT XR launch momentum, $91.7 million fourth-quarter revenue, and its first profitable year as it looks to expand beyond PWS.· February 25, 2026
- Q4 net revenue was $91.7 million, up nearly 40% sequentially from $66 million in Q3, and full-year 2025 net revenue was $190.4 million.
- The company reported full-year 2025 net income of $20.9 million, became cash flow positive, and ended the year with $506.1 million of cash, cash equivalents and marketable securities.
- Commercial launch metrics remained strong: 1,250 patient start forms since launch, 859 active patients at year-end, and 630 unique prescribers.
- Management said launch-to-date discontinuation was about 15% total and about 12% related to adverse events, with long-term discontinuation expected to settle around 15% to 20%.
- Soleno is preparing for a potential EU decision on DCCR in mid-2026 and is advancing GSD 1 as the first new indication for VYKAT XR/DCCR.
Total net revenue for Q4 2025 was $91.7 million, representing sequential growth of nearly 40% from $66 million in Q3. Full-year 2025 net revenue was $190.4 million, with no revenue in the comparable 2024 periods because VYKAT XR was approved in March 2025. The company reported positive net income of $43.4 million in Q4, or $0.82 per basic and $0.80 per diluted share, and full-year net income of $20.9 million, or $0.40 per basic and $0.39 per diluted share, versus a net loss of $175.9 million in 2024. Cash from operating activities was $48.7 million in Q4, and year-end cash, cash equivalents and marketable securities were $506.1 million after a $100 million accelerated share repurchase. For guidance, management said it expects to capture about 1,000 additional start forms over the next 9 to 12 months, anticipates a long-term discontinuation rate of 15% to 20%, expects COGS to nudge up but stay in the mid-single digits as zero-cost inventory burns through, and still anticipates an EMA decision on DCCR in mid-2026.
Anish Bhatnagar described 2025 as a very strong finish to a highly successful launch and emphasized that the company is seeing durable demand, broad stakeholder interest, and real-world safety consistent with expectations. He highlighted 1,250 start forms since launch, 859 active patients, and a belief that Soleno can add roughly 1,000 more start forms over the next 9 to 12 months. He was also constructive on expansion, pointing to DCCR in the EU and GSD 1 as natural next steps while saying the company will keep looking at other high-unmet-need rare diseases.
Jim MacKaness focused on the financial inflection points: $91.7 million of Q4 revenue, $190.4 million for the year, $48.7 million of operating cash flow in Q4, and $506.1 million of year-end liquidity. He also broke out costs, noting Q4 COGS of $0.9 million and full-year COGS of $2.7 million, R&D of $9.6 million in Q4 and $40.6 million for the year, and SG&A of $40.9 million in Q4 and $132.1 million for the year. He said COGS should rise gradually as zero-cost inventory is depleted, but should remain in the mid-single digits, and he noted he is retiring at the end of March with Jennifer Volk taking over as CFO.
Analysts focused on the pace of new start forms, Q1 seasonality, conversion from start forms to active patients, refill rates, and the sustainability of the discontinuation rate. Management said the 1,000-start-form target should be viewed over 9 to 12 months rather than quarter to quarter, and that Q1 will likely see typical commercial seasonality through gross-to-net and co-pay support dynamics. On the patient-conversion gap, management cited roughly a 30-day benefits-assessment lag, and on discontinuations said early signs suggest patients who get through titration tend to stay on therapy, with few dropouts due to lack of efficacy.
The bull case from this call is that VYKAT XR is still early in launch but already producing meaningful revenue, profitability, and cash generation, while patient adoption and prescriber engagement continue to expand. Management also sounded confident that the current momentum can continue, with strong payer coverage, growing caregiver awareness, and a long runway for more start forms, plus optionality from EU DCCR and future rare-disease indications.
The main risks discussed were the normal commercial seasonality in Q1, the lag between start forms and active patients, and the fact that real-world discontinuation and efficacy durability are still being observed only early in launch. Management also acknowledged that EU approval remains uncertain because the EMA’s questions center on the adequacy of the efficacy data, and that future expansion outside PWS, including GSD 1, still requires clinical work and regulatory execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.7%
- Shares Outstanding
- 52.12M
- Float Shares
- 51.46M
of shares held by institutions
280 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 7.10M | ▼ 79.03K |
| Vanguard Group Inc | 3.06M | ▲ 253.21K |
| Axa Investment Managers S.A. | 38.04K | ▲ 38.04K |
| Militia Capital Partners, LP | 35.00K | ▲ 35.00K |
| Midwestone Financial Group, Inc. | 21.82K | ▲ 21.82K |
| Wolverine Trading, LLC | 12.31K | ▲ 5.24K |
| Glenmede Investment Management, LP | 6.45K | ▲ 1.09K |
| Alphaquest LLC | 2.41K | ▲ 608 |
| Comerica Bank | 2.33K | ▼ 164.50K |
| Shell Asset Management Co | 701 | ▼ 939 |
| Eisler Capital Management Ltd. | 303 | ▲ 303 |
| Cibc Private Wealth Group LLC | 62 | ▲ 62 |
Held by 1 ETFs
Biggest fund positions in SLNO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Yen Kristen | sell | 37,639 |
| May 18, 26 | Yen Kristen | sell | 1,741 |
| May 18, 26 | Yen Kristen | sell | 4,999 |
| May 18, 26 | Yen Kristen | sell | 4,000 |
| May 18, 26 | Yen Kristen | sell | 666 |
| May 18, 26 | Yen Kristen | sell | 18,800 |
| May 18, 26 | Yen Kristen | sell | 2,445 |
| May 18, 26 | Yen Kristen | sell | 11,667 |
| May 18, 26 | Yen Kristen | sell | 55,392 |
| May 18, 26 | Yen Kristen | sell | 16,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SLNO coverage
Recent articles, reports, and earnings notes.
No research on SLNO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLNO report →Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm
prnewswire.com · Sep 2
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
prnewswire.com · May 11
SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
newsfilecorp.com · May 5
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
globenewswire.com · May 5
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
globenewswire.com · May 5
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
prnewswire.com · May 5
Halper Sadeh LLC is Investigating Whether SLNO, APLS, HLX are Obtaining Fair Deals for their Shareholders
globenewswire.com · May 5
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
feeds.newsfilecorp.com · May 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.